Effector Therapeutics, a San Diego-based biopharmaceutical company, announced that the company has raised $45 million in a Series A financing round.

The funds will be used to support discovery programs and enable “acquisition of tumor response data in patients for a lead drug candidate” the company said.

Investors in the financing round included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

— SDBJ Staff Report